Literature DB >> 21288144

Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial.

Serkan Yilmaz1, Murat Pekdemir, Umit Tural, Mecit Uygun.   

Abstract

UNLABELLED: OBJECTIVE. Anxiety is an important cause of acute blood pressure (BP) elevation. However, the role of anxiolysis in this situation is still controversial. In this study, the relationship of anxiety with BP and the effect of anxiolytic treatment on BP were investigated. METHODS. Emergency department (ED) patients with an initial systolic BP (SBP) ≥ 160 mmHg or diastolic BP (DBP) ≥ 100 mmHg but no end organ damage were approached for inclusion in the study. In those consenting to participate, anxiety levels were measured using the State-Trait Anxiety Index (STAI) and Visual Analog Scale for Anxiety (VAS-A). Patients were randomly assigned to receive oral alprazolam 0.5 mg or captopril 25 mg. BP and anxiety levels were measured at baseline and at 1 and 2 h after administration of the study medication. RESULTS. Of 133 patients meeting inclusion criteria, 53 patients agreed to participate. Of these, 27 patients (50.9%) received captopril and 26 patients (49.1%) received alprazolam. The majority of the patients had a high-level trait (96.2%, n = 51) and state anxiety (81.1%, n = 43). The mean SBP and VAS-A values of both patient groups dropped significantly over the 2 h, with no significant difference between the two groups. A significant association between SBP and VAS-A scores was found (F((2,50)) = 6.27, p = 0.004).
CONCLUSION: A significant association exists between the level of BP and anxiety in hypertensive ED patients. Alprazolam is as effective as captopril in lowering BP in ED patients with an initial SBP > 160 mmHg.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21288144     DOI: 10.3109/08037051.2011.553934

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  7 in total

Review 1.  Pseudopheochromocytoma: an Uncommon Cause of Severe Hypertension.

Authors:  Christie G Turin; Debbie L Cohen
Journal:  Curr Cardiol Rep       Date:  2022-01-08       Impact factor: 2.931

Review 2.  A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Authors:  Peter Kenneth Gillman
Journal:  J Neural Transm (Vienna)       Date:  2018-09-25       Impact factor: 3.575

3.  Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice.

Authors:  Yong Ye; Hui Gong; Xingxu Wang; Jian Wu; Shijun Wang; Jie Yuan; Peipei Yin; Guoliang Jiang; Yang Li; Zhiwen Ding; Weijing Zhang; Jingmin Zhou; Junbo Ge; Yunzeng Zou
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

4.  Pseudopheochromocytoma Associated with Domestic Assault.

Authors:  H M Le; G Carbutti; D Ilisei; E Bouccin; X Vandemergel
Journal:  Case Rep Cardiol       Date:  2016-09-21

5.  Clonidine versus Captopril for Severe Postpartum Hypertension: A Randomized Controlled Trial.

Authors:  Carlos Noronha Neto C; Sabina S B Maia; Leila Katz; Isabela C Coutinho; Alex R Souza; Melania M Amorim
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

6.  Assessing descriptions of scalability for hypertension control interventions implemented in low-and middle-income countries: A systematic review.

Authors:  Joyce Gyamfi; Dorice Vieira; Juliet Iwelunmor; Beverly Xaviera Watkins; Olajide Williams; Emmanuel Peprah; Gbenga Ogedegbe; John P Allegrante
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

7.  Can Antidepressant Drug Impact on Blood Pressure Level in Patients with Psychiatric Disorder and Hypertension? A Randomized Trial.

Authors:  Seyed Kazem Razavi Ratki; Seyedmostafa Seyedhosseini; Alieh Valizadeh; Tahere Rastgoo; Rozita Tavakkoli; Allahyar Golabchi; Fatemeh Esteki Ghashghaei; Seyede Mahdieh Nemayandeh; Amirreza Boroomand; Atefeh Shirinzade
Journal:  Int J Prev Med       Date:  2016-01-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.